Inmaculada Alfageme1, Pilar de Lucas2, Julio Ancochea1, Marc Miravitlles3, Juan José Soler-Cataluña4, Francisco García-Río5, Ciro Casanova6, José Miguel Rodríguez González-Moro7, Borja G Cosío8, Guadalupe Sánchez9, Joan B Soriano10. 1. Unidad de Gestión Clínica de Neumología, Hospital Universitario Virgen de Valme, Departamento de Medicina, Universidad de Sevilla, Sevilla, España. 2. Servicio de Neumología, Hospital General Gregorio Marańon, Madrid, España. 3. Servicio de Neumología, Hospital Universitari Vall d'Hebron-CIBERES, Barcelona, España. 4. Servicio de Neumología, Hospital Arnau de Vilanova-Lliria, Valencia, España. 5. Servicio de Neumología, Hospital Universitario La Paz-IdiPAZ-CIBERES, Madrid, España. 6. Servicio de Neumología, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, España. 7. Servicio de Neumología, Hospital Universitario de Alcalá de Henares, Madrid, España. 8. Servicio de Neumología, Hospital Universitario Son Espases-IdISBa-Ciberes, Palma de Mallorca, Baleares, España. 9. Departamento Médico, GSK, Tres Cantos, Madrid, España. 10. Consultor de Metodología e Investigación de SEPAR, Barcelona, España; Servicio de Neumología, Hospital Universitario La Princesa, Madrid, España. Electronic address: jbsoriano2@gmail.com.
Abstract
INTRODUCTION: The EPISCAN study, published in 2007, was an update of the results of the 1997 IBERPOC study. Changes in demographics and exposure to risk factors demand the periodic update of prevalence and determining factors in COPD. This article is a summary of the protocol and tools used in EPISCAN II. MATERIALS AND METHODS: The primary objective of EPISCAN II is to estimate the prevalence of COPD among the general population aged 40 years or more in the 17 autonomous communities of Spain. The sample size requires 600 participants (300 men and 300 women) per center, selected by screening 10,200 participants in a short visit (questionnaire plus forced post-bronchodilator spirometry). Of these, 800 (400 with COPD and 400 without COPD) will also perform a long visit (including a walking test, blood tests, determination of diffusion, pulse oximetry and bioimpedance, and low radiation CT). RESULTS: The first participant was recruited on 28 February 2017. As of 22 November 2017, a total of 3,581 participants had been included, of whom 422 had already performed the long visit. It is estimated that the field work will be completed by December 2018. The new imaging data, biomarkers, and information on new exposures, such as electronic cigarettes and environmental pollution, will help us re-quantify the burden of COPD. CONCLUSIONS: EPISCAN II will provide updated information on prevalence and determinants of COPD in Spain, allowing for the comparison of spirometric results and other factors associated with COPD among the 17 autonomous communities.
INTRODUCTION: The EPISCAN study, published in 2007, was an update of the results of the 1997 IBERPOC study. Changes in demographics and exposure to risk factors demand the periodic update of prevalence and determining factors in COPD. This article is a summary of the protocol and tools used in EPISCAN II. MATERIALS AND METHODS: The primary objective of EPISCAN II is to estimate the prevalence of COPD among the general population aged 40 years or more in the 17 autonomous communities of Spain. The sample size requires 600 participants (300 men and 300 women) per center, selected by screening 10,200 participants in a short visit (questionnaire plus forced post-bronchodilator spirometry). Of these, 800 (400 with COPD and 400 without COPD) will also perform a long visit (including a walking test, blood tests, determination of diffusion, pulse oximetry and bioimpedance, and low radiation CT). RESULTS: The first participant was recruited on 28 February 2017. As of 22 November 2017, a total of 3,581 participants had been included, of whom 422 had already performed the long visit. It is estimated that the field work will be completed by December 2018. The new imaging data, biomarkers, and information on new exposures, such as electronic cigarettes and environmental pollution, will help us re-quantify the burden of COPD. CONCLUSIONS: EPISCAN II will provide updated information on prevalence and determinants of COPD in Spain, allowing for the comparison of spirometric results and other factors associated with COPD among the 17 autonomous communities.
Authors: E Bouza; A Alvar; P Almagro; T Alonso; J Ancochea; F Barbé; J Corbella; D Gracia; E Mascarós; J Melis; M Miravitlles; M Pastor; P Pérez; D Rudilla; A Torres; J B Soriano; A Vallano; F Vargas; E Palomo Journal: Rev Esp Quimioter Date: 2020-01-14 Impact factor: 1.553
Authors: Marc Miravitlles; Juan José Soler-Cataluña; Joan B Soriano; Francisco García-Río; Pilar de Lucas; Inmaculada Alfageme; Ciro Casanova; José Miguel Rodríguez González-Moro; M Guadalupe Sánchez-Herrero; Julio Ancochea; Borja G Cosío Journal: Respir Res Date: 2022-03-05
Authors: Elena García Castillo; Tamara Alonso Pérez; Adrián Peláez; Patricia Pérez González; Joan B Soriano; Julio Ancochea Journal: Int J Chron Obstruct Pulmon Dis Date: 2022-09-29
Authors: Zichen Ji; Julio Hernández Vázquez; José María Bellón Cano; Virginia Gallo González; Beatriz Recio Moreno; Alicia Cerezo Lajas; Luis Puente Maestu; Javier de Miguel Díez Journal: J Clin Med Date: 2020-01-15 Impact factor: 4.241
Authors: Zichen Ji; Julio Hernández-Vázquez; Irene Milagros Domínguez-Zabaleta; Ziyi Xia; José María Bellón-Cano; Virginia Gallo-González; Ismael Ali-García; Carmen Matesanz-Ruiz; Ana López-de-Andrés; Rodrigo Jiménez-García; María Jesús Buendía-García; Ángela Gómez-Sacristán; Walther Iván Girón-Matute; Luis Puente-Maestu; Javier de Miguel-Díez Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-10-30